Margaux Boehler

Idorsia (Switzerland) — Switzerland

Pharmacology, Toxicology and Pharmaceutics · Life Sciences

7h-index159citations11works0.02yr avg
OpenAlex↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Pharmacogenetics and Drug Metabolism(2), Inflammatory mediators and NSAID effects(2), Analytical Methods in Pharmaceuticals(2), Glioma Diagnosis and Treatment(1), Blood Pressure and Hypertension Studies(1)

Publications11 total

Clinical pharmacology of the dual orexin receptor antagonist ACT-541468 in elderly subjects: Exploration of pharmacokinetics, pharmacodynamics and tolerability following single-dose morning and repeated-dose evening administration
Journal of Psychopharmacology·2019· 33 cited
Issue Information
The Journal of Clinical Pharmacology·2018Open Access
Clinical Pharmacology of the Reversible and Potent P2Y<sub>12</sub> Receptor Antagonist ACT‐246475 After Single Subcutaneous Administration in Healthy Male Subjects
The Journal of Clinical Pharmacology·2018· 35 cited
Effect of gemfibrozil and rifampicin on the pharmacokinetics of selexipag and its active metabolite in healthy subjects
British Journal of Clinical Pharmacology·2017· 16 citedOpen Access
Biocomparison Study of Adult and Paediatric Dose Strengths of the Prostacyclin Receptor Agonist Selexipag
European Journal of Drug Metabolism and Pharmacokinetics·2017· 8 cited
A pharmacokinetic drug–drug interaction study between selexipag and midazolam, a CYP3A4 substrate, in healthy male subjects
European Journal of Clinical Pharmacology·2017· 18 cited
Effect of Rifampicin on The Pharmacokinetics of Selexipag, An Oral Prostacyclin Receptor Agonist, and Its Active Metabolite In Healthy Male Subjects
Clinical Therapeutics·2017Open Access
Effect of Gemfibrozil on The Pharmacokinetics of Selexipag, An oral Prostacyclin Receptor Agonist, And Its Active Metabolite In Healthy Male Subjects
Clinical Therapeutics·2017
Biocomparison Study of Adult And Pediatric Dose Strengths of The Prostacyclin Receptor Agonist Selexipag
Clinical Therapeutics·2017Open Access
Decitabine Treatment of Glioma-Initiating Cells Enhances Immune Recognition and Killing
PLoS ONE·2016· 40 citedOpen Access
Absolute Bioavailability of Ponesimod, a Selective S1P1 Receptor Modulator, in Healthy Male Subjects
European Journal of Drug Metabolism and Pharmacokinetics·2016· 9 cited

Frequent Co-authors

Jasper Dingemanse(10), Shirin Bruderer(6), Pierre‐Éric Juif(4), Marc Petersen‐Sylla(3), Tatiana Remeňová(3), Atef Halabi(3), Michael Dobrow(2), Mike Ufer(2), Ivan Ulč(2), Cristina Riccadonna(1), Céline Yacoub Maroun(1), Romain Vuillefroy de Silly(1), Marta Calvo Tardón(1), Simone Jueliger(1), Pietro Taverna(1), Leticia Barba(1), Eliana Marinari(1), Serena Pellegatta(1), Esen Yonca Bassoy(1), Denis Martinvalet(1)